Business Practice

Drug emissions in UK rivers raise questions about long-term consequences for the environment.

Sitting Down With... Ajaz Hussain, President, National Institute for Pharmaceutical Technology and Education, Minnesota, USA.

Even plastic used for biopharma manufacturing can be recycled, if we put our minds to it.

The challenge of convincing senior staff to invest in continuous bioprocessing.

Will President Trump’s prices plan deliver for Americans patients?

Pharma TV ads are getting longer, less humorous and more nostalgic — while containing fewer facts.

Concerns abound that post-Brexit border delays could turn the UK into a “second tier state for pharmaceutical imports.”

The cell therapy industry faces a number of complex problems. Fortunately, they’re good problems to have.

The Trump Administration’s plans to move Medicare Part B drugs into the Part D system would mean additional delays and cost barriers for patients.

Biosimilars had their big break in the US in 2015, but three years later biosimilars are still struggling to make a mark.